05.11 2026

Delos and AP Bio Launch Collaboration

Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies

03.30 2026

AP Biosciences, Tasly Amended Collaboration on AP505 (B1962) Out-Licensing

AP Biosciences and Tasly Finalize Amended Collaboration Agreement to Support Global Out-Licensing of AP505 (B1962)

03.24 2026

IBI302 Meets Primary Endpoint in Pivotal Phase III

IBI302 Meets Primary Endpoint in Pivotal Phase III, Demonstrating First-in-Class Anti-VEGF / Anti-Complement Breakthrough